14 results on '"B. Guillonneau"'
Search Results
2. TEP/TDM et récidive biologique d’adénocarcinome prostatique : apport du 68Ga-PSMA-11 lorsque la 18F-fluorocholine n’est pas contributive
- Author
-
O. Bélissant, J. Zhang Yin, B. Guillonneau, A. Girard, Jean-Noël Talbot, Jessica Ohnona, Olivier Cussenot, A.-S. Cottereau, S. Balogova, M. Gauthé, Dominique Pontvert, Thierry Lebret, Valérie Nataf, Université Pierre et Marie Curie - Paris 6 (UPMC), Service de médecine nucléaire [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Curie [Paris], Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Hôpital de la Croix-Saint-Simon, Service d'urologie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Subjects
Gynecology ,medicine.medical_specialty ,Prostate cancer ,business.industry ,PET/CT ,Urology ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Cancer de la prostate ,urologic and male genital diseases ,Récidive biologique ,18F-fluorocholine ,[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology ,Biochemical recurrence ,030218 nuclear medicine & medical imaging ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Ligand du PSMA 68Ga ,Medicine ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,TEP/TDM ,68Ga-PSMA ligand - Abstract
International audience; Introduction: Since April 201, we have introduced PET/CT using a ligand of prostate-specific membrane antigen labeled with gallium-68 (PSMA-11). We aimed to evaluate its positivity rate and impact in patients presenting biochemical recurrence of prostate cancer whose 18F-fluorocholine (FCH) PET/CT was non-contributive.Patients and method: Patients were prospectively included between April and December 2016. PET/CT was performed 60 min after injection of 2 MBq/kg of body mass of 68Ga-PSMA-11. Three anatomical areas were considered: prostatic lodge, pelvic lymph nodes and distant locations. The impact of PSMA-11 PET/CT was assessed by comparing changes in therapeutic strategy decided during multidisciplinary meeting.Results: Thirty-three patients were included. The mean PSA serum level measured on the month of the PSMA-11 PET/CT was 2,8 ng/mL. Twenty-five (76%) PSMA-11 PET/CT were positive, 7 (21%) negative and 1 (3%) equivocal. Of 11 patients whose FCH PET/CT showed equivocal foci, PSMA-11 PET/CT confirmed those foci in 5 cases. Follow-up was available for 18 patients (55%). PSMA-11 PET/CT results led to a change in management in 12 patients (67%).Conclusion: 68Ga-PSMA-11 PET/CT is useful in detecting recurrence of prostate cancer, by identifying residual disease which was not detected on other imaging modalities and by changing management of 2 patients out of 3.Level of evidence: 5.; Introduction: Depuis avril 2016, nous avons introduit la TEP/TDM avec ligand de l’antigène membranaire spécifique de la prostate marqué au gallium-68 (PSMA-11). Nous avons évalué son taux de positivité et son impact chez les patients en récidive biologique de cancer de prostate, sans lésion affirmable en TEP/TDM à la 18F-fluorocholine (FCH).Patients et méthodes: Ces patients ont été prospectivement inclus d’avril à décembre 2016. La TEP/TDM a été effectuée 60 min après injection de 2 MBq/kg de 68Ga-PSMA-11. Trois sites anatomiques ont été considérés : loge prostatique, ganglions pelviens, et localisations à distance. L’impact des résultats de la TEP/TDM-PSMA-11 sur la prise en charge a été évalué en comparant les stratégies thérapeutiques proposées lors des réunions de concertation pluridisciplinaires.Résultats: Trente-trois patients ont été inclus. La concentration sérique moyenne du PSA mesurée au cours du mois de la TEP/TDM-PSMA-11 était de 2,8 ng/mL. Vingt-cinq TEP/TDM-PSMA-11 (76 %) étaient positives, 7 (21 %) négatives et 1 (3 %) douteuse. Sur 11 patients dont la TEP/TDM-FCH était douteuse, la TEP/TDM-PSMA-11 a confirmé les lésions douteuses dans 5 cas. Un suivi était disponible pour 18 patients (55 %). Les résultats des TEP/TDM-PSMA-11 ont conduit à un changement de la prise en charge chez 12 patients (67 %).Conclusion: La TEP/TDM au 68Ga-PSMA-11 est efficace dans la localisation de la récidive du cancer de la prostate, identifiant des cibles de maladie résiduelle non visualisées par les autres méthodes d’imagerie, changeant ainsi la prise en charge de 2 patients sur 3.Niveau de preuve: 5.
- Published
- 2017
- Full Text
- View/download PDF
3. Formación en oncología urológica laparoscópica: La experiencia del Memorial Sloan-Kettering Cancer Center
- Author
-
B. Guillonneau and Karim Touijer
- Subjects
Laparoscopic surgery ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Urology ,education ,Urologic Oncology ,Formación ,Surgery ,Laparoscopia ,Dry lab ,Urología oncológica ,medicine ,Surgical skills ,Medical physics ,Surgical education ,Training program ,Laparoscopy ,business ,Accreditation - Abstract
Objetivo: Presentar un breve esquema de la estructura del programa clínico y de formación en oncología urológica laparoscópica en el Memorial Sloan-Kettering Cancer Center. Describir las fases y los elementos claves necesarios para adquirir la capacitación en laparoscopia. Material y métodos: El programa dura 2 años y forma a residentes en formación y a urólogos. En el caso de los residentes, el programa consiste en una rotación en oncología con un gran volumen de procedimientos laparoscópicos, de 6 meses de duración, en el cual se adquiere experiencia en laboratorio de simulación, laboratorio animal, revisión de vídeos y experiencia en quirófano. Para los urólogos, el programa consiste en 1 curso de formación médica continuada acreditada, 20 horas de laboratorio de simulación, 1 sesión de laboratorio animal, observación de casos laparoscópicos, ejercer como primer ayudante en un mínimo de 15 procedimientos laparoscópicos y ejecución de procedimientos laparoscópicos bajo supervisión. Resultados: 8 residentes han completado el programa de formación laparoscópica, 4 de los cuales han completado su ciclo de especialización y están en centros académicos, realizando laparoscopia avanzada. El abordaje supone un promedio del 80% de su práctica urológica. Tres de los participantes están realizando cirugía laparoscópica bajo supervisión. Conclusión: Los objetivos de un programa de formación quirúrgica deberían ser la normalización de la adquisición de experiencia quirúrgica y la evaluación de los resultados en un marco uniforme para garantizar la conservación de la experiencia adquirida y desarrollar programas para enseñar nuevas técnicas.
- Published
- 2006
- Full Text
- View/download PDF
4. DNA adducts in normal bladder tissue and bladder cancer risk.
- Author
-
S. Benhamou, A. Laplanche, B. Guillonneau, A. Mejean, F. Desgrandchamps, C. Schrameck, V. Degieux, and F. Perin
- Subjects
SMOKING ,BLADDER cancer ,DOSE-response relationship in biochemistry ,DNA - Abstract
Cigarette smoking is an established cause of bladder cancer. The direct relationship between smoking-induced DNA adducts in bladder cells and cancer risk at that site has, however, been poorly assessed. We therefore investigated the relationship between bladder cancer risk and levels of DNA adducts measured in normal bladder biopsies by
32 P-post-labeling in a hospital-based case-control study of 59 bladder cancer patients and 45 controls submitted to surgery for prostatic hyperplasia or urinary incontinence. An approximately 2-fold risk for bladder cancer was found in individuals with an adduct level >14.8 (median among controls) compared with those with an adduct level ≤14.8 (OR = 1.9, 95% CI 0.8-4.3, P = 0.13). A dose-response relationship was also suggested (trend test, P = 0.13): compared with adduct levels below 13.5, the OR for bladder cancer was 1.7 (95% CI 0.6-4.6) for adduct levels between 13.5 and 18.5 and 2.2 (95% CI 0.8-6.1) for adduct levels >18.5. These findings provide some evidence that DNA adducts in bladder tissue might predict smoking-induced bladder cancer. Larger studies are still warranted to confirm these results. [ABSTRACT FROM AUTHOR]- Published
- 2003
- Full Text
- View/download PDF
5. Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence.
- Author
-
Rasmussen M, Fredsøe J, Tin AL, Vickers AJ, Ulhøi B, Borre M, Eastham J, Ehdaie B, Guillonneau B, Laudone V, Scardino PT, Touijer K, Sørensen KD, and Lilja H
- Subjects
- Humans, Male, Neoplasm Grading, Prostate pathology, Prostate-Specific Antigen, Prostatectomy, Kallikreins, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery
- Abstract
Background: Accurate markers for prostate cancer (PC) risk stratification could aid decision-making for initial management strategies. The 4Kscore has an undefined role in predicting outcomes after radical prostatectomy (RP)., Methods: We included 1476 patients with 4Kscore measured prior to RP at two institutions. The 4Kscore was assessed for prediction of adverse pathology at RP and biochemical recurrence (BCR) relative to a clinical model. We pre-specified that all analyses would be assessed in biopsy Grade Group 1 (GG1) or 2 (GG2) PC patients, separately., Results: The 4Kscore increased discrimination for adverse pathology in all patients (delta area under the receiver operative curve (AUC) 0.009, 95% confidence interval (CI) 0.002, 0.016; clinical model AUC 0.767), driven by GG1 (delta AUC 0.040, 95% CI 0.006, 0.073) rather than GG2 patients (delta AUC 0.005, 95% CI -0.012, 0.021). Adding 4Kscore improved prediction of BCR in all patients (delta C-index 0.014, 95% CI 0.007, 0.021; preop-BCR nomogram C-index 0.738), again with larger changes in GG1 than in GG2., Conclusions: This study validates prior investigations on the use of 4Kscore in men with biopsy-confirmed PC. Men with GG1 PC and a high 4Kscore may benefit from additional testing to guide treatment selection. Further research is warranted regarding the value of the 4Kscore in men with biopsy GG2 PC., (© 2021. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2022
- Full Text
- View/download PDF
6. Alternative surgical approach for inflatable penile prosthesis removal.
- Author
-
Alhammadi A, Abdessater M, Althobity A, Kanbar A, Sleiman W, Guillonneau B, Zugail A, and Beley S
- Abstract
Competing Interests: Competing interestsDr. Sebastien Beley works as a consultant for Coloplast and in Advance Medical Technology companies. Otherwise, we have no conflict of interests nor financial interests to be disclosed.
- Published
- 2020
- Full Text
- View/download PDF
7. Sleep related painful erection: an algorithm for evaluation and management.
- Author
-
Abdessater M, Kanbar A, Zugail AS, Al Hammadi A, Guillonneau B, and Beley S
- Abstract
Background: Sleep related painful erection (SRPE) is a rare parasomnia consisting of nocturnal penile tumescence accompanied by pain that awakens the individual. Normal non-painful erections are experienced when awake. No penile anatomic abnormalities are present. No conclusive randomized clinical trial is present in the literature about the management of this rare condition. The aim of this article is to review the current knowledge about the management of SRPE and to suggest an algorithm to help physicians evaluate and manage SRPE., Material and Methods: A literature review was conducted through PubMed database using the terms: sleep, pain, painful, penile, and erection. The reference lists of the articles were also reviewed. The search returned 23 references that were published between 1987 and 2019. Results were presented in a descriptive manner., Results: Treatment decision for now is based on reports of the treatment success, the sustainability of remission, the tolerability by the patients and the potential side effects of each medication. From data available in literature, Baclofen is the mostly used medication with a tolerable profile of adverse effects. Phosphodiesterase type 5 inhibitors are considered potential treatments and are already widely used and tolerated for other indications, but so far only 2 successful trials have been reported for SRPE. Cinitapride is very promising, but only one case was studied and no side effects were reported. Clozapine can be very dangerous although highly effective., Conclusion: Based on the limited number of treatment trials and reported cases, the low level of evidence and the lack of randomized clinical trials, no treatment consensus for SRPE can be reached. We suggested a useful tool for clinicians: an algorithm for the management of SRPE to facilitate their access to the literature without exhaustive return to case reports and series upon each case faced., Competing Interests: Competing interestsAuthors declare that they have no competing interests for this article., (© The Author(s). 2019.)
- Published
- 2019
- Full Text
- View/download PDF
8. Splenorenal fusion mimicking renal cancer: One case report and literature review.
- Author
-
Zugail AS, Ahallal Y, Comperat EM, and Guillonneau B
- Abstract
Splenorenal fusion is an extremely rare benign entity. This abnormality is presented in a case of a 29-year-old-male patient. We discuss the distinction between this condition and renal splenosis and their embryology. The course of this condition and modalities of investigation including radiological imaging, management, and pitfalls are reviewed., Competing Interests: There are no conflicts of interest.
- Published
- 2019
- Full Text
- View/download PDF
9. Angiomyxoma of the ureter imitating an upper tract urothelial carcinoma: A case report.
- Author
-
Zugail AS, Baowaidan F, Comperat EM, Guillonneau B, and Colau A
- Abstract
Introduction: Angiomyxomas are rare benign neoplasms of mesenchymal origin arising from the soft tissues of the perineum and pelvis., Case Presentation: To our knowledge, we report the first case of ureteral angiomyxoma arising de novo in a fifty-four-year-old female patient who presented with macroscopic hematuria., Discussion: The pathological findings, radiological features and operative management will be discussed., Conclusion: Angiomyxomas are notorious for their locally infiltrative nature and their propensity to recur. Clinical suspicion is capital to reach the diagnosis and a holistic care is key to a good outcome., (Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
10. Pudendal schwannoma: A case report and literature review.
- Author
-
Mazzola CR, Power N, Bilsky MH, Robert R, and Guillonneau B
- Abstract
Schwannomas are benign nerve sheath tumours most often associated with the cranial nerves and the peripheral nerve system of the neck and extremities. Pelvic schwannomas are rare, with only about 25 cases reported. We report the case of a 34-year-old man referred for worsening pain of 10 years duration involving the right testicle and right penile shaft. Magnetic resonance imaging discovered a well-circumscribed pelvic tumour of 3.2 × 2.8 × 3.2 cm. Considering the possible complications involved in exposing the pudendal nerve during surgical resection, we performed an extensive literature search to aid preoperative planning. The most commonly described surgical approach for pelvic schwannomas has been open median laparotomy with transperitoneal dissection. To our knowledge, pudendal schwannomas have never been described in the literature. However, after considering the location and characteristics of the tumour, we chose laparoscopy because it offers the advantages of better visualization of anatomical structures with minimal invasiveness and faster recovery. At the 3-week follow-up, the patient described a significant decrease in pain and normal neurological and urological examinations.
- Published
- 2014
- Full Text
- View/download PDF
11. Genetic polymorphisms in 85 DNA repair genes and bladder cancer risk.
- Author
-
Michiels S, Laplanche A, Boulet T, Dessen P, Guillonneau B, Méjean A, Desgrandchamps F, Lathrop M, Sarasin A, and Benhamou S
- Subjects
- Adult, Aged, Cell Cycle genetics, DNA Polymerase beta genetics, DNA Replication genetics, Fanconi Anemia Complementation Group A Protein genetics, Female, Humans, Male, Middle Aged, Paris, Reference Values, Risk Factors, Smoking epidemiology, Urinary Bladder Neoplasms pathology, White People genetics, DNA Repair genetics, Polymorphism, Genetic, Urinary Bladder Neoplasms epidemiology, Urinary Bladder Neoplasms genetics
- Abstract
Several defense mechanisms have been developed and maintained during the evolution to protect human cells against damage produced from exogenous or endogenous sources. We examined the associations between bladder cancer and a panel of 652 polymorphisms from 85 genes involved in maintenance of genetic stability [base excision repair, nucleotide excision repair, double-strand break repair (DSBR) and mismatch repair, as well as DNA synthesis and cell cycle regulation pathways] in 201 incident bladder cancer cases and 326 hospital controls. Score statistics were used to test differences in haplotype frequencies between cases and controls in an unconditional logistic regression model. To account for multiple testing, we associated to each P-value the expected proportion of false discoveries (q-value). Haplotype analysis revealed significant associations (P < 0.01) between bladder cancer and two genes (POLB and FANCA) with an associated q-value of 24%. A permutation test was also used to determine whether, in each pathway analyzed, there are more variants whose allelic frequencies are different between cases and controls as compared with what would be expected by chance. Differences were found for cell cycle regulation (P = 0.02) and to a lesser extent for DSBR (P = 0.05) pathways. These results hint to a few potential candidate genes; however, our study was limited by the small sample size and therefore low statistical power to detect associations. It is anticipated that genome-wide association studies will open new perspectives for interpretation of the results of extensive candidate gene studies such as ours.
- Published
- 2009
- Full Text
- View/download PDF
12. DNA adducts in normal bladder tissue and bladder cancer risk.
- Author
-
Benhamou S, Laplanche A, Guillonneau B, Mejean A, Desgrandchamps F, Schrameck C, Degieux V, and Perin F
- Subjects
- Aged, Biopsy, Case-Control Studies, Female, Humans, Leukocytes physiology, Male, Phosphorus Radioisotopes, Predictive Value of Tests, Reference Values, Risk Factors, Smoking, DNA Adducts analysis, Urinary Bladder physiology, Urinary Bladder Neoplasms genetics
- Abstract
Cigarette smoking is an established cause of bladder cancer. The direct relationship between smoking-induced DNA adducts in bladder cells and cancer risk at that site has, however, been poorly assessed. We therefore investigated the relationship between bladder cancer risk and levels of DNA adducts measured in normal bladder biopsies by 32P-post-labeling in a hospital-based case-control study of 59 bladder cancer patients and 45 controls submitted to surgery for prostatic hyperplasia or urinary incontinence. An approximately 2-fold risk for bladder cancer was found in individuals with an adduct level >14.8 (median among controls) compared with those with an adduct level < or =14.8 (OR = 1.9, 95% CI 0.8-4.3, P = 0.13). A dose-response relationship was also suggested (trend test, P = 0.13): compared with adduct levels below 13.5, the OR for bladder cancer was 1.7 (95% CI 0.6-4.6) for adduct levels between 13.5 and 18.5 and 2.2 (95% CI 0.8-6.1) for adduct levels >18.5. These findings provide some evidence that DNA adducts in bladder tissue might predict smoking-induced bladder cancer. Larger studies are still warranted to confirm these results.
- Published
- 2003
- Full Text
- View/download PDF
13. Laparoscopic radical prostatectomy: assessment after 550 procedures.
- Author
-
Guillonneau B, Cathelineau X, Doublet JD, Baumert H, and Vallancien G
- Subjects
- Humans, Male, Perioperative Care, Postoperative Complications, Prostatectomy adverse effects, Prostatectomy instrumentation, Treatment Outcome, Laparoscopy, Prostatectomy methods
- Abstract
Purpose: To evaluate our experience in laparoscopic radical prostatectomy., Materials and Methods: Between January 1998 and December 2000, 550 consecutive patients eligible for radical prostatectomy, were operated laparoscopically. Data concerning surgery and post-operative course were assessed and recorded. Oncological data were assessed by pathological examination and post-operative PSA level. Functional results were assessed with a self-questionnaire., Results: The mean operating time was 170 min for the last 350 patients. Surgical conversion was necessary in seven patients (1.3%). Mean intra-operative bleeding was 290 ml (range: 50-1500 ml) for the last 350 patients. The overall transfusion rate was 5.27%. Mean bladder catheterization time was 4.2 days and median postoperative stay was 5 days in the last 350 patients. By pathological stage, 4 pT2a specimens (3.3%), 48 pT2b specimens (15%), 21 pT3a specimens (33%), 19 pT3b specimens (47%) were found to have positive surgical margins. For pT2a and pT2b stages, non-biological recurrence probability (PSA<0.1 ng/ml) is, respectively, 92.3% at 36 months, and 86.3% at 31 months. The continence rate (no pad) was 82.3% at 12 months among the 255 first patients. For 47 consecutive selected patients, spontaneous erection rate was 85 and 66% experienced spontaneous intercourse., Conclusions: Laparoscopic radical prostatectomy is currently feasible, with low perioperative morbidity. Taking into account the postoperative follow-up, oncological results are identical to those obtained with conventional surgery. The functional results are encouraging.
- Published
- 2002
- Full Text
- View/download PDF
14. [Localized prostatic cancer: treatment with laparoscopic radical prostatectomy: study with 841 cases].
- Author
-
Vallancien G, Guillonneau B, Cathelineau X, Baumert H, and Doublet JD
- Subjects
- Humans, Male, Laparoscopy, Prostatectomy methods, Prostatic Neoplasms surgery
- Abstract
The authors present their experience in the technique of laparoscopic radical prostatectomy. After 841 operations done from January 1998 to april 2001. They use a trans peritoneal approach with 5 ports of 5 and 10 mm. The prostatectomy is done antegrady and the urethrovesical anastomosis is rebuilt with interrupted 3/0 resorbable sutures. Operating time is 2 hours and 40 minutes (1 h 30 to 6 h 30) Conversion rate is 0.9%, average bleeding is 330 cc and transfusion rate is 2.8%. Bladder catheter is removed between days 3 to 6. hospital stay is 5.8 days. Post-op pain is minimal (2% of antalgics at day 2). There was no death, no embolism, 0.2% of phlebitis, 1.1% of rectal injury. Anstomotic strictures occur in 0.3% of cases. 89.2% of patients are continent after 1 year and 75% of patients under 70 years old who underwent a bilateral nerve sparing procedure were potent at 6 months. Positive margins were observed in 5% of pT2a, 22.5% of pT2b, 22.7% in pT3a and 30% in PT3b. After 2 years 92.5% of patients pT2a and b have a PSA < 0.1 ng/ml. No port seeding or peritoneal invasion by cancer was observed. Laparoscopic radical prostatectomy is a safe surgical procedure which limits the risk of transfusion, of anastomotic stricture, which reduces post op pain and allows a good continence. Potency recovery is promising.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.